{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:27:43Z","timestamp":1787725663532,"version":"build-2784847793"},"reference-count":165,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology. This is highlighted by the success of agents that interrupt PD-1 mediated immune suppression in a range of cancers. However, while PD-1 blockade has been paradigm-shifting in many malignancies, the majority of cancers show high rates of primary resistance to this approach. This has led to a rapid expansion in therapeutic targeting of other immune checkpoint molecules to provide combination immune checkpoint blockade (ICB), with one such promising approach is blockade of Lymphocyte Activation Gene 3 (LAG-3). Clinically, lymphoproliferative disorders show a wide spectrum of responses to ICB. Specific subtypes including classical Hodgkin lymphoma have demonstrated striking efficacy with anti-PD-1 therapy. Conversely, early trials of ICB have been relatively disappointing in common subtypes of Non-Hodgkin lymphoma. In this review, we describe the TME of common lymphoma subtypes with an emphasis on the role of prominent immune checkpoint molecules PD-1 and LAG3. We will also discuss current clinical evidence for ICB in lymphoma and highlight key areas for further investigation where synergistic dual checkpoint blockade of LAG-3 and PD-1 could be used to overcome ICB resistance.<\/jats:p>","DOI":"10.3390\/cells10051152","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:49:51Z","timestamp":1620643791000},"page":"1152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma"],"prefix":"10.3390","volume":"10","author":[{"given":"Joshua W. D.","family":"Tobin","sequence":"first","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Bednarska","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlea","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9934","authenticated-orcid":false,"given":"Colm","family":"Keane","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, QLD 4102, Australia"},{"name":"Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.20061937","article-title":"Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection","volume":"204","author":"Shin","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","article-title":"CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1","volume":"72","author":"Fourcade","year":"2012","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1919082","DOI":"10.1155\/2019\/1919082","article-title":"Beyond T Cells: Understanding the Role of PD-1\/PD-L1 in Tumor-Associated Macrophages","volume":"2019","author":"Lu","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_15","first-page":"58","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Zhou","year":"2018","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1165\/rcmb.2004-0129OC","article-title":"Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells","volume":"33","author":"Kim","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Shin","year":"2017","journal-title":"Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/17474086.2016.1235970","article-title":"PD-1 blockade in Hodgkin\u2019s lymphoma: Learning new tricks from an old teacher","volume":"9","author":"Allen","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","article-title":"Checkpoint inhibitors in hematological malignancies","volume":"10","author":"Ok","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gellrich, F.F., Schmitz, M., Beissert, S., and Meier, F. (2020). Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010223"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1002\/cam4.2625","article-title":"Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab","volume":"8","author":"Moser","year":"2019","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fromentin, R., Bakeman, W., Lawani, M.B., Khoury, G., Hartogensis, W., DaFonseca, S., Killian, M., Epling, L., Hoh, R., and Sinclair, E. (2016). CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005761"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9495","article-title":"Immunological biomarkers predict HIV-1 viral rebound after treatment interruption","volume":"6","author":"Hurst","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"Embo J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG 3 (CD 223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: Results of a Phase I trial","volume":"12","author":"Romano","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-19-3548","article-title":"FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity","volume":"26","author":"Kraman","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_57","first-page":"9513701","article-title":"Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives","volume":"2019","author":"Stalder","year":"2019","journal-title":"J. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00428-011-1140-8","article-title":"Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma","volume":"459","author":"Zaki","year":"2011","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3324\/haematol.2011.055459","article-title":"Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin\u2019s lymphoma","volume":"97","author":"Medeiros","year":"2012","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3109\/10428194.2011.580026","article-title":"The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma","volume":"52","author":"Jakovic","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2010.031542","article-title":"Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma","volume":"96","author":"Kamper","year":"2011","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.leukres.2013.03.021","article-title":"Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma","volume":"37","author":"Casulo","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/10428194.2014.917636","article-title":"CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment","volume":"56","author":"Touati","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1878-0261.12616","article-title":"High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination","volume":"14","author":"Arlt","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Meti, N., Esfahani, K., and Johnson, N.A. (2018). The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10060204"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"El Halabi, L., Adam, J., Gravelle, P., Marty, V., Danu, A., Lazarovici, J., Ribrag, V., Bosq, J., Camara-Clayette, V., and Laurent, C. (2020). Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2020.11.009"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD4+ T cells in PD-1 blockade against MHC-II\u2013expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2018-99-112830","article-title":"Elevated LAG-3 Expression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis","volume":"132","author":"Keane","year":"2018","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kuruvilla, J., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N.A., Fogliatto, L.M., Goncalves, I., de Oliveira, J.S.R., and Buccheri, V. (2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol.","DOI":"10.1016\/S1470-2045(21)00005-X"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1\/2 Study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2019-127280","article-title":"Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/bloodadvances.2019001367","article-title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"4","author":"Armand","year":"2020","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.104_2629","article-title":"NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP","volume":"37","author":"Ansell","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Goergen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/jco.2015.33.18_suppl.lba109","article-title":"Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)","volume":"33","author":"Horn","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin Lymphoma with Reduced \u03b22M\/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.beha.2018.07.001","article-title":"The unique biology and treatment of primary mediastinal B-cell lymphoma","volume":"31","author":"Broccoli","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","article-title":"Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up","volume":"10","author":"Zhou","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Takata, K., Aoki, T., Chong, L.C., Milne, K., Miyata-Takata, T., Singh, K., Goodyear, T., Farinha, P., Slack, G.W., and Sehn, L.H. (2020). Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma. Blood, 136.","DOI":"10.1182\/blood-2020-141462"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1080\/10428194.2019.1620942","article-title":"Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma","volume":"60","author":"Sethi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Furuse, M., Kuwabara, H., Ikeda, N., Hattori, Y., Ichikawa, T., Kagawa, N., Kikuta, K., Tamai, S., Nakada, M., and Wakabayashi, T. (2020). PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. Bmc Cancer, 20.","DOI":"10.1186\/s12885-020-06755-y"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.2018.197194","article-title":"PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma","volume":"103","author":"Pollari","year":"2018","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Pollari, M., Pellinen, T., Karjalainen-Lindsberg, M.L., Kellokumpu-Lehtinen, P.L., Leivonen, S.K., and Lepp\u00e4, S. (2020). Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Eur. J. Haematol.","DOI":"10.1111\/ejh.13484"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"87317","DOI":"10.18632\/oncotarget.20264","article-title":"Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Cho, I., Lee, H., Yoon, S.E., Ryu, K.J., Ko, Y.H., Kim, W.S., and Kim, S.J. (2020). Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6612-2"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2375","article-title":"PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival","volume":"35","author":"Four","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_113","first-page":"5655","article-title":"Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study","volume":"37","author":"Hayano","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.1038\/s41598-019-46473-5","article-title":"Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1\/Th-2 status is guaranteed for prognosis prediction in PCNSL","volume":"9","author":"Takashima","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00262-020-02575-y","article-title":"In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy","volume":"69","author":"Marcelis","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_117","first-page":"2731","article-title":"The Impact of EBV upon the Tumor Microenvironment and Mutational Profile of Primary CNS Lymphoma in PTLD","volume":"130","author":"Gandhi","year":"2017","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3960\/jslrt.18001","article-title":"The expression of PD-1 ligands and IDO1 by macrophage\/microglia in primary central nervous system lymphoma","volume":"58","author":"Miyasato","year":"2018","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin\u2019s lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2015-08-663997","article-title":"Cell-specific PD-L1 expression in DLBCL","volume":"126","author":"Boussiotis","year":"2015","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"45370","DOI":"10.18632\/oncotarget.9659","article-title":"The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1038\/s41598-017-11052-z","article-title":"Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: Clinical features and survival impact","volume":"7","author":"Cohen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.2019000889","article-title":"EBV microRNA-BHRF1-2-5p targets the 3\u2032UTR of immune checkpoint ligands PD-L1 and PD-L2","volume":"134","author":"Cristino","year":"2019","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"28125","DOI":"10.18632\/oncotarget.15924","article-title":"MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biopha.2017.11.146","article-title":"Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1","volume":"98","author":"He","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s11658-019-0190-9","article-title":"MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1","volume":"24","author":"Sun","year":"2019","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1756116","DOI":"10.1080\/2162402X.2020.1756116","article-title":"Genomic and immunologic correlates of LAG-3 expression in cancer","volume":"9","author":"Panda","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.18632\/oncotarget.26771","article-title":"The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma","volume":"10","author":"Chen","year":"2019","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: A novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A unifying microenvironment model in follicular lymphoma: Outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols","volume":"94","author":"Koster","year":"2009","journal-title":"Haematologica"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ejh.12075","article-title":"Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era","volume":"90","author":"Takahashi","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation","volume":"4","author":"Frigault","year":"2020","journal-title":"Blood Adv."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-141773","article-title":"First Results of the Acs\u00e9 Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort","volume":"136","author":"Houot","year":"2020","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_157","first-page":"637","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"BloodJ. Am. Soc. Hematol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1182\/blood-2019-123908","article-title":"Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the \u20181st FLOR\u2019 Study","volume":"134","author":"Barraclough","year":"2019","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus\u2012Positive and \u2012Negative Relapsed or Refractory Non-Hodgkin Lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_161","first-page":"P232","article-title":"Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies","volume":"4","author":"Lipson","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/hum.2017.234","article-title":"Nucleofection with Plasmid DNA for CRISPR\/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells","volume":"30","author":"Hu","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:58:52Z","timestamp":1760162332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":165,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cells10051152"],"URL":"https:\/\/doi.org\/10.3390\/cells10051152","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]}}}